Gastroenterology and Functional Medicine
https://www.hksmp.com/journals/gfm
<p>Gastroenterology and Functional Medicine (GFM) delivers up-to-date basic and clinical research in the field of gastroenterology and hepatology. Original research should focus on clinical and basic-translational content, including cohort studies, clinical trials, epidemiological studies, novel mechanisms and diagnostic research. GFM also aims to minimize the gap between basic and clinical science through publishing comprehensive reviews, case reports, commentary and translational research with clear application on important topics such as inflammatory bowel diseases, functional gastrointestinal disorders and liver diseases.</p>en-USwilson.zhang@gfmjournal.com (Wison Zhang)stanleyzhang@sppub.org (Stanley Zhang)Tue, 27 May 2025 15:16:26 +0800OJS 3.3.0.7http://blogs.law.harvard.edu/tech/rss60Liver status and metabolic-dysfunction associated steatotic liver disease/steatohepatitis presence by Fibroscan® in patients with chronic hepatitis B: A Faraday study
https://www.hksmp.com/journals/gfm/article/view/893
<p><strong>Background</strong><strong> and Objectives</strong>: Evaluation of liver fibrosis is imperative in the management of chronic hepatitis B. Metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) with necroinflammation contribute significantly to liver damage. This study aims to investigate the role of vibration-controlled transient elastography (FibroScan®) as a non-invasive method for diagnosis and treatment follow-up. <strong>Methods</strong>: The study was prospectively planned in four different centers. Patients who were positive for hepatitis B surface antigen for more than 6 months and had an HBV-DNA > 2000 IU/mL underwent liver biopsy and FibroScan®. FibroScan® was performed before antiviral therapy and 1 year after treatment. <strong>Results</strong>: A total of 70 patients were included in the study. The mean age was 37.1 years, and 70.0% of the patients were male. The concordance rate with simultaneous elastography in 68 biopsies was 97.1% (<em>P</em> < 0.001). In 66 patients (97.0%), the liver fibrosis score was ≥ 2 or the hepatic activity index was ≥ 6. At the beginning of antiviral treatment, 19 patients (27.1%) had MASLD and 6 patients (8.6%) had MASH. The MASLD rate decreased to 25.7% (<em>P</em> = 0.064), and there was no change in MASH rate at the end of 1 year. The concordance rate with liver biopsy was found to be acceptable. <strong>Conclusion</strong>: FibroScan® was as useful as liver biopsy in the evaluation of chronic viral hepatitis-associated fibrosis as well as in the diagnosis and follow-up of concomitant MASLD/MASH.</p>Mustafa Kemal Celen, Cigdem Mermutluoglu, Fethiye Akgul, Pinar Cakmak, Tuba Damar Cakirca, Ismail Yildiz, Yesim Tasova, Yasar Bayindir
Copyright (c) 2025 Gastroenterology and Functional Medicine
https://www.hksmp.com/journals/gfm/article/view/893Tue, 27 May 2025 00:00:00 +0800